Schisandrin B induces an Nrf2‐mediated thioredoxin expression and suppresses the activation of inflammasome in vitro and in vivo
Authors:
- 26 August 2015
- journal article
- research article
- Published by Wiley in BioFactors
- Vol. 41 (5) , 314-323
Abstract
Reactive oxygen species (ROS)‐mediated activation of inflammasome is involved in the development of a wide spectrum of diseases. We aimed to investigate whether (−)schisandrin B [(−)Sch B], a phytochemical that can induce cellular antioxidant response, can suppress the inflammasome activation. Results showed that (−)Sch B can induce an nuclear factor erythroid 2‐related factor 2‐driven thioredoxin expression in primary peritoneal macrophages and cultured RAW264.7 macrophages. A 4‐h priming of peritoneal macrophages with LPS followed by a 30‐min incubation with ATP caused the activation of caspase 1 and the release of IL‐1β, indicative of inflammasome activation. Although LPS/ATP did not activate inflammasome in RAW264.7 macrophages, it caused the ROS‐dependent c‐Jun N‐terminal kinase1/2 (JNK1/2) activation and an associated lactate dehydrogenase (LDH) release in RAW264.7 macrophages, an indication of cytotoxicity. (−)Sch B suppressed the LPS/ATP‐induced activation of caspase 1 and release of IL‐1β in peritoneal macrophages. (−)Sch B also attenuated the LPS/ATP‐induced ROS production, JNK1/2 activation and LDH release in RAW264.7 macrophages. The ability of (−)Sch B to suppress LPS/ATP‐mediated inflammation in vitro was further confirmed by an animal study, in which schisandrin B treatment (2 mmol/kg p.o.) ameliorated the Imject Alum‐induced peritonitis, as indicated by suppressions of caspase1 activation and plasma IL‐1β level. The ensemble of results suggests that (−)Sch B may offer a promising prospect for preventing the inflammasome‐mediated disorders. © 2015 BioFactors, 41(5):314–323, 2015Keywords
Funding Information
- GRF grant (661113)
This publication has 29 references indexed in Scilit:
- Inflammasome and cytokine blocking strategies in autoinflammatory disordersClinical Immunology, 2013
- Schisandrin B exerts anti-neuroinflammatory activity by inhibiting the Toll-like receptor 4-dependent MyD88/IKK/NF-κB signaling pathway in lipopolysaccharide-induced microgliaEuropean Journal of Pharmacology, 2012
- The NLRP3 inflammasome in health and disease: the good, the bad and the uglyClinical and Experimental Immunology, 2011
- The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistanceNature Medicine, 2011
- Schisandrin B elicits a glutathione antioxidant response and protects against apoptosis via the redox-sensitive ERK/Nrf2 pathway in AML12 hepatocytesFree Radical Research, 2010
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsNature, 2010
- Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 ExpressionThe Journal of Immunology, 2009
- Immune and Inflammatory Mechanisms of AtherosclerosisAnnual Review of Immunology, 2009
- Schisandrin B stereoisomers protect against hypoxia/reoxygenation-induced apoptosis and inhibit associated changes in Ca2+-induced mitochondrial permeability transition and mitochondrial membrane potential in H9c2 cardiomyocytesLife Sciences, 2008
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005